Introduction {#s1}
============

Low-and-middle income countries (LMICs) are facing concurrent epidemics of communicable and non-communicable diseases.[@R1] Unlike high-income countries, the prevalence of non-communicable diseases has rapidly and continuously risen in the past decades in LMICs.[@R2] This increasing burden of non-communicable diseases is particularly true for cardiovascular diseases (CVD), including stroke, coronary heart disease, peripheral arterial disease and heart failure.[@R2] [@R3] The high CVD-related morbidity and mortality observed in LMICs are paralleled by the increasing prevalence of lifestyle risk factors in these countries, especially hypertension.[@R4] Hypertension, once rare in traditional African societies,[@R5] [@R6] has become a major public health problem because of high prevalence rates contrasting with low awareness, treatment and control rates.[@R7] The high prevalence of hypertension in Africa is due to both urbanisation and a shift towards western habits such as smoking, unhealthy diets with excess salt and fat intake, physical inactivity and consequential increased adiposity, and increasingly recognised non-traditional risk factors such as air pollution.[@R5] [@R10] [@R11]

High blood pressure (BP) tracks from childhood to adulthood, such that children presenting with high BP (HBP) are at high risk of becoming hypertensive at an adult age.[@R5] [@R12] Emerging data from developed populations also suggest that, as in adults, primary hypertension is more common than secondary hypertension in the paediatric population.[@R6] [@R15] Furthermore, the presence of HBP has been linked to end-organ damage (particularly left ventricular hypertrophy and kidney failure) and subclinical atherosclerosis.[@R6] [@R16] [@R17] Hence, in western countries, it is strongly recommended to measure BP in all children ≥3 years of age in the course of routine healthcare, [@R18] in order to promote cardiovascular health in adults.

It is difficult to estimate the prevalence of hypertension in the paediatric population because BP relates to sex, age and height during childhood, making it complicated to consider a single BP value as in adults.[@R14] [@R16] [@R18] [@R19] Nevertheless, many epidemiological studies summarised in systematic reviews have attempted this issue in high-income countries, and reported an increasing burden of hypertension in children and adolescents,[@R16] with prevalence rates of 1--5%.[@R20] [@R21] This is not the case for African countries where there is a considerable variability of the estimated prevalence among studies conducted in South Africa and certain West African countries (0--22.3%).[@R5] [@R6] [@R19] [@R22] [@R23] Additionally, there is no reported incidence of hypertension among children in Africa, to the best of our knowledge, as well as limited evidence for its risk factors.

Thus, it is unclear whether the growing epidemic of hypertension in the African adult population is reflected in children and adolescents. The fast transition towards CVD in Africa, together with the increasing awareness of hypertension in children by African health professionals involved in paediatric care, stresses the need to build an accurate epidemiology of hypertension in children and adolescents in this part of the world. Along these lines, we present the protocol for a systematic review and meta-analysis to estimate the prevalence and incidence rates of hypertension among African children and adolescents, as well as its risk factors. Results are intended to provide an essential basis for designing cost-effective interventions that can be introduced early in life to prevent the burden of CVD in adulthood.

Objective {#s2}
=========

To conduct a systematic review and meta-analysis to estimate the prevalence and the incidence of hypertension among children and adolescents in Africa, as well as its risk factors.

Review question {#s2a}
---------------

This review of studies published in the past 30 years, from 1 January 1985 to 30 April 2015, should answer the following questions: What is the prevalence of HBP among African children and adolescents residing in Africa?What is the incidence of HBP among African children and adolescents?Which factors are associated with HBP among African children and adolescents?

Criteria for considering studies for the review {#s2b}
-----------------------------------------------

### Inclusion criteria {#s2b1}

We will include: Cross-sectional, case--control or cohort studies of children and adolescents aged 1--18 years residing in African countries reporting the prevalence or incidence of HBP, or enough data to compute these estimates.Studies including assessment of office and/or ambulatory and/or home BP, as well as those evaluating risk factors for hypertension in African children and adolescents.Studies with a diagnosis of hypertension based on BP ≥95th centile.Studies published in English or French, unpublished studies and conference proceedings.

Exclusion criteria {#s2c}
------------------

1.  Studies on non-systemic hypertension (intracranial hypertension, pulmonary hypertension).

2.  Studies conducted among populations of African origin residing outside of Africa.

3.  Studies in subgroups of participants selected on the basis of the presence of hypertension (eg, clinical trials).

4.  Studies including adult and paediatric populations in which it will not be possible to extract data of children and/or adolescents.

5.  Case series with small sample size (less than 50 participants), letters, reviews, commentaries and editorials.

6.  Studies lacking primary data and/or explicit method description.

7.  Duplicates: for studies published in more than one paper, the most comprehensive one reporting the largest sample size will be considered.

8.  Studies with serious ethical issues.

9.  Studies whose full data will not be accessible even after request from the authors.

Search strategy for identifying relevant studies {#s2d}
------------------------------------------------

This systematic review and meta-analysis will follow the guidelines set out by MOOSE.[@R24] The search strategy will be implemented in two stages:

### Bibliographic database searches {#s2d1}

Relevant abstracts published in English or French on the prevalence, the incidence and the risk factors for HBP in children and adolescents in Africa will be identified via searching PubMed, Google Scholar and online African journals. The search will be limited to studies published between 1 January 1985 and 31 July 2015. Both text words and medical subject heading terms will be used. Key search terms will be: Africa, children, adolescents, prevalence, incidence, risk factors and hypertension. We will also use individual country names for the 53 African countries and hypertension as additional key search terms for more abstracts on the subject. Conference proceedings of the study period will also be identified through Medline and checked. The main search strategy is shown in [table 1](#BMJOPEN2015008472TB1){ref-type="table"}.The abstracts of all eligible papers will be reviewed and full articles will be accessed through PubMed, Google Scholar, HINARI or journals' websites. The references of all the relevant research articles will also be scrutinised for additional potential data sources, and their full texts will be accessed in a similar way. The authors whose full text papers will not be accessible by the numerous internet-based sources will be directly contacted to provide them. In case of no feedback from these authors, the corresponding studies will be excluded.

###### 

Search method in PUBMED

  Search   Search terms
  -------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1        Hypertension \[tw\] OR high blood pressure \[tw\] OR systolic hypertension \[tw\] OR diastolic hypertension \[tw\]
  2        Hypertension \[MeSH terms\]
  3        \# 1 OR \# 2
  4        (Child \[tw\] OR Child \[MeSH terms\] Children \[tw\] OR childhood \[tw\] OR adolescent \[MeSH terms\] OR adolescent \[tw\] OR adolescent\* \[tw\] OR pediatric \[tw\] OR teens \[tw\] OR teen \[tw\] OR Teenage\* \[tw\] OR Youth\* \[tw\] OR Infan\* \[tw\])
  5        \# 3 AND \# 4
  6        ((((("Africa\"\[MeSH\] OR Africa\* \[tw\] OR Algeria\[tw\] OR Angola\[tw\] OR Benin\[tw\] OR Botswana\[tw\] OR "Burkina Faso\"\[tw\] OR Burundi \[tw\] OR Cameroon \[tw\] OR "Canary Islands" \[tw\] OR "Cape Verde" \[tw\] OR "Central African Republic" \[tw\] OR Chad \[tw\] OR Comoros \[tw\] OR Congo \[tw\] OR "Democratic Republic of Congo" \[tw\] OR Djibouti \[tw\] OR Egypt \[tw\] OR "Equatorial Guinea" \[tw\] OR Eritrea \[tw\] OR Ethiopia \[tw\] OR Gabon \[tw\] OR Gambia \[tw\] OR Ghana \[tw\] OR Guinea \[tw\] OR "Guinea Bissau" \[tw\] OR "Ivory Coast" \[tw\] OR "Cote d\'Ivoire" \[tw\] OR Jamahiriya \[tw\] OR Jamahiryia \[tw\] OR Kenya \[tw\] OR Lesotho \[tw\] OR Liberia \[tw\] OR Libya \[tw\] OR Libia \[tw\] OR Madagascar \[tw\] OR Malawi \[tw\] OR Mali \[tw\] OR Mauritania \[tw\] OR Mauritius \[tw\] OR Morocco \[tw\] OR Mozambique \[tw\] OR Mocambique \[tw\] OR Namibia \[tw\] OR Niger \[tw\] OR Nigeria \[tw\] OR Principe \[tw\] OR Reunion \[tw\] OR Rwanda \[tw\] OR "Sao Tome" \[tw\] OR Senegal \[tw\] OR Seychelles \[tw\] OR "Sierra Leone" \[tw\] OR Somalia \[tw\] OR "South Africa" \[tw\] OR "St Helena" \[tw\] OR Sudan \[tw\] OR Swaziland \[tw\] OR Tanzania \[tw\] OR Togo \[tw\] OR Tunisia \[tw\] OR Uganda \[tw\] OR "Western Sahara" \[tw\] OR Zaire \[tw\] OR Zambia \[tw\] OR Zimbabwe \[tw\] OR "Central Africa" \[tw\] OR "Central African" \[tw\] OR "West Africa" \[tw\] OR "West African" \[tw\] OR "Western Africa" \[tw\] OR "Western African" \[tw\] OR "East Africa" \[tw\] OR "East African" \[tw\] OR "Eastern Africa" \[tw\] OR "Eastern African" \[tw\] OR "North Africa" \[tw\] OR "North African" \[tw\] OR "Northern Africa" \[tw\] OR "Northern African" \[tw\] OR "South African" \[tw\] OR "Southern Africa" \[tw\] OR "Southern African" \[tw\] OR "sub Saharan Africa" \[tw\] OR "sub Saharan African" \[tw\] OR "subSaharan Africa" \[tw\] OR "subSaharan African" \[tw\]) NOT ("guinea pig" \[tw\] OR "guinea pigs" \[tw\] OR "aspergillus niger" \[tw\])))))
  7        \# 5 AND \# 6
  8        \#7 Limits: 1985/01/01 to 2015/04/30 and studies done in Humans, in English and French

### Selection of studies for inclusion in the review {#s2d2}

Assessment of eligible papers will be done by three members of the team independently, and using an assessment guide to ensure that the selection criteria are reliably applied by all the investigators. They will also consensually retain the studies that will be included in the review, and any disagreement will be solved by a fourth assessor.

Assessment of methodological quality and data reporting {#s2e}
-------------------------------------------------------

The Risk of Bias Tool for Prevalence Studies developed by Hoy *et al*[@R25] (see online supplementary material appendix S1), and the Cochrane guidelines available in Review Manager V.5.3 (<http://tech.cochrane.org/revman>) will be used to assess the methodological quality and risk of bias for each study. The STROBE checklist (see online supplementary material appendix S2)[@R26] will be used to evaluate the reporting methodology in each paper. Risk of bias and quality scores will be presented in a table.

Data extraction and management {#s2f}
------------------------------

A data extraction sheet will be used to collect information about the country, the year of publication, the language of publication, the type of publication, the study design, the number of participants, the mean age of the population, the diagnostic criteria for hypertension, the prevalence and the incidence of hypertension, as well as its predictive factors when available. Where prevalence/incidence rates or information for calculating them (eg, sample size, number of outcomes) are lacking, we will directly contact the corresponding author to request the information. In case of multinational studies, we will separate the results to show the prevalence, the incidence and risk factors within individual countries. Where it will not be possible to disaggregate the data by country, the study will be presented as one and the countries in which the study was done will be shown.

Statistical analysis {#s2g}
--------------------

Data will be analysed using Stata software (Stata Corp V.13, Texas, USA). A meta-analysis will be conducted for data obtained from studies in which hypertension was defined identically. SEs for the study-specific estimates will first be determined from the point estimate and the appropriate denominators, assuming a binominal (or Poisson for incidence data) distribution. Then the study-specific estimates will be pooled through a random-effects meta-analysis model, to obtain an overall summary estimate of the prevalence/incidence across studies, after stabilising the variance of individual studies using the Freeman-Tukey double arc-sine transformation.[@R27] A meta-analysis will be performed to assess the association between risk factors and hypertension.

Heterogeneity will be evaluated by the χ^2^ test on Cochrane[@R28]\'s Q statistic, which is quantified by I^2^ values,[@R29] assuming that I^2^ values of 25%, 50% and 75%, respectively, represent low, medium and high heterogeneity. Where substantial heterogeneity will be detected, a subgroup analysis will be performed to detect its possible sources using the following grouping variables: age group, sex, study setting (hospital vs community-based), geographical area (central, eastern, northern, southern and western Africa), study quality. Inter-rater agreement for study inclusion will be assessed using Cohen\'s κ coefficient.[@R30] Funnel plots analysis and Egger\'s test[@R31] will be done to detect publication bias.

Results will be presented by geographic region (central, eastern, northern, southern and western Africa). A p value less than 0.05 will be considered significant for factors that predicted hypertension.

Results reporting and presentation {#s2h}
----------------------------------

The study selection process will be summarised using a flow diagram. Reasons for studies' exclusion will be described. This will follow the MOOSE Guidelines for Meta-Analyses and Systematic Reviews of Observational Studies.[@R24] Quantitative data will be presented in evidence tables of individual studies as well as in summary tables and funnel plots where appropriate. We will examine prevalence/incidence and risk factors by region, setting (hospital or community), time period and disease-specific populations depending on the data available. We plan to report on quality scores and risk of bias for each eligible study. This may be tabulated and accompanied by narrative summaries.

Conclusion {#s2i}
----------

Hypertension, a major driver of the CVD burden in Africa, has reached epidemic proportions in the adult population. Given that children and adolescents presenting with HBP have a major risk of becoming hypertensive adults, specific cost-effective interventions need to be introduced early in life to prevent CVD in adulthood. Prior to these strategies, accurate epidemiological data should be obtained. We wish that this review will guide policy, practice and research by providing information on the magnitude of hypertension among African children, as well as its risk factors, and the remaining gaps that may form the basis for future studies.

A major possible limitation of this study could be the limited data with predominance of hospital-based studies and poor quality data when available. Another possible limitation may be the heterogeneity of studies, making further analysis difficult. In addition, there may be a predominance of cross-sectional studies, making it difficult to obtain reliable incidence estimates and to determine risk factors for hypertension. Other drawbacks might include the non-random selection of participants, and the under-representation of some geographical areas such as Central Africa. These problems have already been noted by previous reviews on non-communicable diseases in Africa,[@R1] [@R8] [@R32] and might be reinforced by the fact that BP is still not routinely recorded in paediatric consultations in many African countries. Finally, since we will include only studies published in English or French, we may lose relevant data from countries where these languages are not spoken.

Ethics and dissemination {#s3}
========================

This study is based on published data, and therefore ethical approval is not a requirement. This systematic review and meta-analysis is expected to serve as a basis for designing preventive and control strategies early in life, and as a guide for future research based on the remaining gaps. The final report of this study in the form of a scientific paper will be published in peer-reviewed journals. Findings will further be presented at conferences and submitted to relevant health authorities. We also plan to update the review in the future to monitor changes and guide health service and policy solutions.
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